Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $31.1 Million - $42.6 Million
-440,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $25.7 Million - $39.2 Million
440,000 New
440,000 $38.1 Million
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $13.2 Million - $24.1 Million
-147,315 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $12.1 Million - $20.6 Million
147,315 New
147,315 $13.1 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $313M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.